Glycomacropeptide Ameliorates Indomethacin-Induced Enteropathy in Rats by Modifying Intestinal Inflammation and Oxidative Stress

Autor: Laura E. Córdova-Dávalos, Eva Salinas, Vanessa Ruiz-Esparza Palacios, Daniel Cervantes-García, Armida I Bahena-Delgado, Esperanza Sánchez-Alemán, Mariela Jiménez, María Consolación Martínez-Saldaña
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Chemokine CXCL1
Indomethacin
Interleukin-1beta
Nitric Oxide Synthase Type II
Pharmaceutical Science
oxidative damage
Hematocrit
Pharmacology
neutrophil infiltration
medicine.disease_cause
Occludin
Analytical Chemistry
chemistry.chemical_compound
0302 clinical medicine
Drug Discovery
Enteropathy
Intestinal Mucosa
0303 health sciences
glycomacropeptide
medicine.diagnostic_test
biology
Caseins
Milk Proteins
Nitric oxide synthase
medicine.anatomical_structure
Chemistry (miscellaneous)
Molecular Medicine
030211 gastroenterology & hepatology
Protein-Losing Enteropathies
inflammatory mediators
mucosal barrier integrity
Article
Nitric oxide
lcsh:QD241-441
03 medical and health sciences
lcsh:Organic chemistry
medicine
Animals
Humans
Physical and Theoretical Chemistry
030304 developmental biology
Inflammation
Mucin-2
nonsteroidal anti-inflammatory drugs
business.industry
Organic Chemistry
Albumin
medicine.disease
Peptide Fragments
Small intestine
Rats
intestinal damage
Disease Models
Animal
Oxidative Stress
Gene Expression Regulation
chemistry
biology.protein
business
Oxidative stress
Zdroj: Molecules
Volume 25
Issue 10
Molecules, Vol 25, Iss 2351, p 2351 (2020)
ISSN: 1420-3049
DOI: 10.3390/molecules25102351
Popis: Nonsteroidal anti-inflammatory drug (NSAID)-induced enteropathy is considered a serious and increasing clinical problem without available treatment. Glycomacropeptide (GMP) is a 64-amino acid peptide derived from milk k-casein with numerous biological activities. The aim of this study was to investigate the protective effect of GMP on NSAID enteropathy in rats. Enteropathy was induced by seven days oral indomethacin administration. Rats were orally GMP treated from seven days previous and during the establishment of the enteropathy model. Changes in metabolism, hematological and biochemical blood alterations, intestinal inflammation and oxidative damage were analyzed. Integrity barrier markers, macroscopic intestinal damage and survival rate were also evaluated. GMP treatment prevented anorexia and weight loss in animals. Furthermore, prophylaxis with GMP ameliorated the decline in hemoglobin, hematocrit, albumin and total protein levels. The treatment had no therapeutic efficacy on the decrease of occludin and mucin (MUC)-2 expression in intestinal tissue. However, GMP markedly decreased neutrophil infiltration, and CXCL1, interleukin-1&beta
and inducible nitric oxide synthase expression. Nitric oxide production and lipid hydroperoxide level in the small intestine were also diminished. These beneficial effects were mirrored by preventing ulcer development and increasing animal survival. These results suggest that GMP may protect against NSAID enteropathy through anti-inflammatory and antioxidant properties.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje